The technology offers measurable benefits without sacrificing insertion accuracy, according to new research. 

Recent projections could create an environment of unprecedented demand for nuclear imaging.

Bayer’s latest contrast agent is proving its potential in clinical trials as a promising alternative to agents with higher gadolinium content.